Daniel Getman joins Sucampo's board
This article was originally published in Scrip
Sucampo Pharmaceuticals has elected Dr Daniel Getman to its board of directors. Dr Getman is currently president of the Kansas City Area Life Sciences Institute, and was previously vice-president of Pfizer global research and development and director of Pfizer's St Louis laboratories. Dr Getman joins Sucampo as Andrew Ferrara, a director since July 2008, resigns.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.